MILAN, Italy — BetaGlue® Therapeutics (“BetaGlue” or the “Company”), a pioneering Italian clinical-stage oncology company developing an innovative radiotherapy solution for the targeted treatment of solid tumours, is proud to announce that the Belgium Ministry of Health (MOH) has approved its Clinical Trial Application for YntraDose® in the treatment of unresectable Locally...
Latest News
Grateful parents are putting the national spotlight on a school for helping their daughter cope with a rare condition. James and Kerry Satelle have nominated Ysgol Glan Gele reception class teacher Laura Martin for the Welsh Teacher of the Year award for the work she did in allowing leukodystrophy sufferer...
SAN FRANCISCO, Calif. — Better Therapeutics, Inc. (NASDAQ: BTTX), a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its novel Cognitive Behavioral Therapy (CBT) platform intended to treat adults with metabolic...
New York, NY – There’s a frustrating fact about today’s immunotherapies for cancer. While sometimes they work beautifully — completely eliminating or greatly reducing cancer in particular patients — other times they don’t work at all. It’s a mystery. Scientists have posed several hypotheses to explain the disparity. Perhaps it’s...
TOSSE, France – While Bruton’s tyrosine kinase inhibitors are often hailed as the next big breakthrough in multiple sclerosis, Immunic Therapeutics and others are leveraging neuroprotective targets and remyelination to keep the disease at bay. One of the largest gatherings of multiple sclerosis researchers took place in Barcelona last month,...
HAMILTON, Bermuda — Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. and a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that the Phase 1 Study evaluating UNO in advanced, relapsed or refractory unresectable, primary or metastatic cutaneous and...
PHILADELPHIA, PA — Beyond Celiac, the leading catalyst for a cure for celiac disease, today announces the creation of Beyond Celiac Investments (BCI), an investment program to accelerate the development of treatments and a cure for celiac disease by leveraging the speed and scale of venture capital and capital markets....
– The UK approval is based on positive results from the Phase 3 ATTRibute-CM study, in which acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date – In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated The approval was based on a Japanese Phase 3 study and the global ATTRibute-CM Phase 3 trial, which demonstrated the most rapid benefit seen in any Phase 3 study of...
MENLO PARK, Calif. — BillionToOne (BTO), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, is pleased to announce a global collaboration with Janssen Research & Development, LLC, a Johnson & Johnson company (Johnson & Johnson), in the AZALEA Phase 3...